Opthea’s lead product candidate, sozinibercept, is being evaluated as of Q2 2024 in two pivotal Phase III clinical trials for use in combination with standard-of-care anti-VEGF-A monotherapies to improve overall efficacy and deliver superior vision gains compared to standard-of-care anti-VEGF-A agents.

The company operates in Australia and is administered by its head office in South Yarra, Victoria.

Opthea Limited is listed on the ASX under the code OPT.